1. HOME
  2. Company
  3. Abrax History

COMPANY

Information

Abrax Company History

Abrax History

2020
01/2020

Abrax Project initiated by Dr. Taku Kambayashi

Co-founder, Dr. Kambayashi’s intent to bring his decades of basic research to fruition
01/2020

Mr. Jo Narita’s inauguration as the CEO

Bringing in vast experience in the global business for acceleration of commercialization
05/2020

Abrax Japan established

A corporation established in Japan with Seed 1 funding
07/2020

Seed 2 fundraise

¥190 million raised from a venture capital and private investors
08/2020

Business partnership with Camargo

Establishment of a regulatory strategy team for new drug approval through business partnership
08/2020

Business partnership with Tergus Biopharma

Initiation of new drug formulation with Tergus Biopharma through business partnership
09/2020

Seed 3 fundraise

JPY 50 million raised from private investors
2021
03/2021

Completion of ABX-919 formulation

A new formulation produced by Tergus Biopharma and code-named “ABX-919”
07/2021

Publication in one of the most prominent journals in the world by Dr. Kambayashi

Dr. Kambayashi’s research published in the journal Science (Vol. 373, Issue 6554)
08/2021

Seed 4 fundraise

JPY 250 million raised from the existing investors to support a pre-clinical and clinical studies
08/2021

Reaching over JPY 1 billion in corporate valuation

Surpassing JPY 1 billion in corporate valuation upon completion of Seed 4 fundraise
08/2021

Establishment of Australian subsidiary

Establishment of Abrax Australia Pty. Ltd. for execution of clinical trials in Australia

And our stories continue…